Get the Stockscreener App
15.48
10.63%
-2.01
Tonix Pharmaceuticals Holding Corp stock is traded at $15.48, with a volume of 806.16K.
It is down -10.63% in the last 24 hours and up +100.38% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$17.49
Open:
$17.15
24h Volume:
806.16K
Relative Volume:
0.51
Market Cap:
$105.21M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.3748
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-22.51%
1M Performance:
+100.38%
6M Performance:
+12.12%
1Y Performance:
-97.39%
1-Day Range:
$14.70
$17.49
1-Week Range:
$14.70
$23.28
52-Week Range:
$7.31
$672.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
15.55 | 105.21M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.45 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.56 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.13 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.76 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
241.21 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Peering Into Tonix Pharmaceuticals's Recent Short Interest - Benzinga
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewswire
Tonix Pharma stock rises following TONIX ONE launch - Investing.com Australia
Tonix Pharma stock rises following TONIX ONE launch By Investing.com - Investing.com UK
Tonix Pharmaceuticals launches migraine management platform - Investing.com
Tonix Pharmaceuticals launches migraine management platform By Investing.com - Investing.com Canada
Tonix Pharmaceuticals Launches TONIX ONE™, a - GlobeNewswire
Game-Changing Digital Platform Transforms How Patients Track and Treat Migraines - Stock Titan
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year - ACCESS Newswire
Revolutionary Non-Opioid Pain Drug Could Transform Fibromyalgia Treatment by 2025 - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - Bluefield Daily Telegraph
(TNXP) Long Term Investment Analysis - Stock Traders Daily
Tonix Pharmaceuticals Announces Presentation at the - GlobeNewswire
Fast-Tracked Fibromyalgia Treatment: Tonix Showcases Breakthrough Pain Drug Data Before FDA Decision - StockTitan
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha
Noble Capital maintains Outperform on Tonix Pharma, $70 target By Investing.com - Investing.com South Africa
Noble Capital maintains Outperform on Tonix Pharma, $70 target - Investing.com
Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (TNXP) - Seeking Alpha
Pharma Frenzy: Volatility Ignites Biotech Sector - Benzinga
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Tonix advances fibromyalgia drug, eyes Q4 2025 launch By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment; Shares Up - MarketScreener
Tonix advances fibromyalgia drug, eyes Q4 2025 launch - Investing.com India
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment - Marketscreener.com
Tonix Pharmaceuticals stock soars on FDA update By Investing.com - Investing.com Australia
Tonix Pharmaceuticals stock soars on FDA update - Investing.com
Tonix Pharma’s TNX-102 SL Advances in FDA Process - TipRanks
Tonix Pharmaceuticals Announces that FDA Will Not Require - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Advances: FDA Expedites TNX-102 SL Review - Stock Titan
Tonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail’s Feeling Bullish - MSN
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread - BioSpace
New Single-Dose Mpox Vaccine Outperforms Existing Options as Cases Surge Worldwide - StockTitan
Tonix Pharma stock drops after Q4 revenue miss (TNXP:NASDAQ) - Seeking Alpha
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Reports 2024 Financial Results and Pipeline Progress - TipRanks
Tonix Pharmaceuticals stock tumbles on earnings miss - Investing.com India
Tonix Pharma earnings missed by $5.86, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals stock tumbles on earnings miss By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp. SEC 10-K Report - TradingView
Tonix Pharmaceuticals 8-K Filing Analysis - TradingView
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - GlobeNewswire
Tonix Secures Path to First New Fibromyalgia Drug in 15 Years with $98.8M War Chest - StockTitan
Learn to Evaluate (TNXP) using the Charts - Stock Traders Daily
* Tonix pharmaceuticals announces 1-for-10 reverse stock split - Reuters
Tonix Pharmaceuticals secures MCDC grant to advance next-gen Mpox & Smallpox vaccine development - Proactive Investors USA
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 - GlobeNewswire
Major FDA Decision Looms: Tonix's Revolutionary Fibromyalgia Treatment Could End 15-Year Innovation Drought - StockTitan
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.65%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):